Cellectis (CLLS) Stock Price, News & Analysis

Company Overview

Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases. Its pipeline has included UCART programs targeting blood cancers, with research focused on improving the persistence, safety and activity of off-the-shelf engineered immune-cell products. The company advances its programs through internal research, clinical development and strategic collaborations.

Founded in 1999, Cellectis has operations and research activities in France and the United States, serving the global biopharmaceutical and oncology markets. The company has also pursued collaborations with larger pharmaceutical companies, including AstraZeneca, to support the development of gene-edited cell therapies. Cellectis is headquartered in Paris, France, and is led by co-founder André Choulika, who has served as chief executive officer.

Key Stats

• Today's Range: $1.43 to $1.50
• 50-Day Range: $1.38 to $3.56
• 52-Week Range: $1.25 to $5.48
• Volume: 58,046 shs
• Average Volume: 53,331 shs
• Market Capitalization: $148.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.46
• Consensus Rating: Hold

Cellectis Stock Analysis - MarketRank™

Cellectis scored higher than 64% of companies evaluated by MarketBeat, and ranked 309th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Cellectis has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Cellectis has a consensus price target of $5.46, representing about 267.4% upside from its current price of $1.49.

Amount of Analyst Coverage

Cellectis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectis is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectis is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectis has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.58% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently increased by 68.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectis does not currently pay a dividend.

Dividend Growth

Cellectis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.20

News Sentiment

Cellectis has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cellectis this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for CLLS on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Cellectis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/28/2026
• Stifel 2026 Virtual Cardiometabolic Forum: 9/30/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLLS
• CIK: 1627281
• Web: www.cellectis.com
• Phone: (318) 169-1600
• Fax: 33-1-81-69-16-06
• Employees: 229
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellectis: $5.46
• High Price Target: $8.00
• Low Price Target: $1.30
• Potential Upside/Downside: +268.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.59 million
• Net Margins: -102.34%
• Pretax Margin: -102.89%
• Return on Equity: -94.19%
• Return on Assets: -21.34%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 1.37
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $79.59 million
• Price / Sales: 1.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.76 per share
• Price / Book: 1.95

Miscellaneous

• Outstanding Shares: 100,340,000
• Free Float: 83,873,000
• Market Cap: $148.50 million
• Optionable: Optionable
• Beta: 2.92